To expand current knowledge, we examined the safety and tolerability of subcutaneous interferon b-1a in patients with pediatriconset multiple sclerosis. Records from 307 patients who had received at least 1 injection of subcutaneous interferon b-1a for demyelinating events when aged younger than 18 years were reviewed. Overall, 168 (54.7%) patients had at least 1 prespecified medical event related to or under close monitoring with subcutaneous interferon b-1a or specific to pediatric patients, 184 (59.9%) had nonserious medical events related to treatment or of unknown causality, and 12 (3.9%) had serious medical events irrespective of causality. The most common laboratory abnormalities were increased alanine (74/195; 37.9%) and aspartate aminotransferase levels (59/194; 30.4%). Annualized relapse rates were 1.79 before treatment and 0.47 during treatment. In conclusion, adult doses of subcutaneous interferon b-1a (44 and 22 mg, 3 times weekly) were well tolerated in pediatric patients and were associated with reduced relapse rates.
The onset of multiple sclerosis most frequently occurs at 20 to 40 years of age. 1 However, it is estimated that 3% to 5% of patients experience their first symptoms before the age of 16 years, [2] [3] [4] [5] and less than 1% before the age of 10 years. 4, 6 In 98% of pediatric patients with multiple sclerosis, the disease initially follows a relapsing-remitting course. 7 Studies suggest that the onset of secondary progressive disease occurs later after the first attack in pediatric patients than in patients with adult-onset disease. 4, 7, 8 However, patients with childhoodonset multiple sclerosis reach the secondary progressive phase and have irreversible disability at younger ages than patients with adult-onset multiple sclerosis. 4, 7, 8 In adults with multiple sclerosis, disease-modifying drugs are recommended soon after diagnosis or at the first attack (provided clinical, laboratory, and magnetic resonance imaging features are consistent with multiple sclerosis), as clinical trials have demonstrated the benefits of early treatment. [9] [10] [11] [12] [13] [14] However, these trials did not enroll patients younger than 18 years. Given the potential severe long-term consequences of pediatric multiple sclerosis, the current recommendations are that children and adolescents with multiple sclerosis should be treated with disease-modifying drugs, and that treatment, as for adults, should be started as early as possible in the disease course, and not delayed until adulthood. [15] [16] [17] [18] Pediatric data on the use of interferon-b therapies, although available, are limited due to small sample sizes. Small cohort studies and isolated case reports indicate that interferon-b therapies are well tolerated and appear to be effective in the treatment of pediatric multiple sclerosis. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] To capture more comprehensive experience with subcutaneous interferon b-1a in a large, multinational pediatric multiple sclerosis population, this study reviewed the safety and tolerability of subcutaneous interferon b-1a in children and adolescents with demyelinating events, based on retrospective data from medical records. Although the study was not designed to evaluate efficacy, additional data were collected to explore the impact of treatment on clinical relapses.
Methods

Study Design
This was a retrospective, phase IV study (ClinicalTrials.gov identifier: NCT01207648) conducted at 18 centers, in the United States (6 sites); Italy (6 sites); and Russia, Argentina, Canada, France, Tunisia, and Venezuela (1 site each). Data were retrieved from medical health care records of patients evaluated between 1997 and 2009. The observation period for an individual patient began with the first medical record available on site and ended on December 31, 2009, or when the patient was lost to follow-up, whichever occurred first.
The study was conducted in accordance with the Declaration of Helsinki, Guidelines for Good Pharmacoepidemiology Practices, International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulations. An Institutional Review Board or Independent Ethics Committee approved the protocol as required by local laws. All patient data were recorded anonymously.
Study Population
Patients were eligible if they had received at least 1 injection of subcutaneous interferon b-1a for demyelinating events before the age of 18 years. Treatment with subcutaneous interferon b-1a must have been initiated prior to June 2009 to allow at least 6 months of possible observation for each patient. To minimize the potential bias inherent in retrospective patient selection, the aim was to assess all pediatric patients treated with subcutaneous interferon b-1a at each center. Therefore, for centers to participate in the study, it was essential that medical records were available for all patients treated with immunomodulatory drugs, including patients who died, became adults and moved to adult clinics, or were lost to follow-up.
Outcomes
The primary focus of the study was the safety and tolerability of subcutaneous interferon b-1a in a population with pediatric-onset multiple sclerosis. Data were collected on prespecified medical events of special interest, regardless of severity and causality. Prespecified medical events comprised medical events known to be related to subcutaneous interferon b-1a, such as injection-site reactions, influenza-like symptoms, blood cell disorders, hepatic disorders, allergic reactions, and thyroid disorders; medical events likely to occur in a pediatric population with or without multiple sclerosis, such as epilepsy and convulsive disorders, and bone/epiphyseal and cartilage disorders; and medical events under close monitoring with subcutaneous interferon b-1a, such as malignancies, serious infections, and autoimmune diseases.
Nonserious medical events considered by the investigator as related to treatment were recorded; nonserious medical events of unknown causality were collected by some sites and included in the analysis. Serious medical events, irrespective of causality, were also collected. Medical events that were listed as prespecified medical events could be counted again as nonserious and serious medical events. Only medical events that occurred after the initiation of subcutaneous interferon b-1a were eligible for analysis, including medical events that occurred after discontinuation of subcutaneous interferon b-1a therapy. Causality of medical events was assigned retrospectively only if well documented in the medical records. Laboratory parameters collected from the time of subcutaneous interferon b-1a initiation to the end of the observation period included total white blood cell count, differential hematology count, serum aspartate aminotransferase and alanine aminotransferase levels, and thyroid function (thyroid-stimulating hormone concentration).
Efficacy outcomes included medically confirmed clinical relapses, defined as the emergence of new neurologic symptoms that occurred more than 30 days after a previous attack and persisted for at least 24 hours in the absence of known intercurrent illness. All records reporting clinical relapses were reviewed by members of the study steering committee to ensure relapses occurring in the pretreatment and treatment phases were evaluated reliably.
Statistical Analysis
Safety and tolerability data were analyzed descriptively for all patients in the study (total analysis set) and in 2 subgroups based on age at subcutaneous interferon b-1a initiation: children (aged <12 years) and adolescents (aged 12 to <18 years). Efficacy outcomes were evaluated only in patients with a final diagnosis of multiple sclerosis (multiple sclerosis analysis set). The annualized rate of medically confirmed clinical relapses was analyzed by Poisson regression with no covariates. For pretreatment attack rates, as every patient is considered to have 1 or more attacks prior to starting subcutaneous interferon b-1a treatment, the data were transformed by deducting 1 clinical attack for each patient, fitting a Poisson regression based on the transformed data, and retransforming the estimates of the Poisson regression by adding 1. For annualized relapse rates during subcutaneous interferon b-1a treatment, and from the end of subcutaneous interferon b-1a treatment until the end of observation, the log of the time on observation was used as the offset variable. A sensitivity analysis was performed by evaluating the annualized rate of medically confirmed clinical relapses in patients who were observed for at least 6 months before and after subcutaneous interferon b-1a initiation. The median times to the first medically confirmed clinical relapse, after the first demyelinating event and after starting subcutaneous interferon b-1a therapy, were evaluated using Kaplan-Meier cumulative probability estimates. All comparisons were purely exploratory and descriptive. Interpretation of results was based on point estimates and the corresponding 95% confidence intervals, not P values. All statistical analyses were performed using SAS version 9.1 (or higher) software (SAS Institute Inc, Cary, NC, USA).
A sample size calculation was not performed for this study as all patients who met the eligibility criteria at the participating centers were to be included. It was expected that data from approximately 250 patients would be available for analysis.
Results Patients
A total of 307 patients were included in the total analysis set (United States, n ¼ 139; Italy, n ¼ 47; Russia, n ¼ 38; Argentina, n ¼ 33; France, n ¼ 23; Canada, n ¼ 21; Tunisia and Venezuela, n ¼ 3 each). Data from 2 patients were collected but not included in the total analysis set as it could not be confirmed that these patients were aged younger than 18 years at the start of subcutaneous interferon b-1a treatment. Of the 307 patients, 298 had a final diagnosis of multiple sclerosis and were included in the multiple sclerosis analysis set. All participating centers were able to produce the required information from the first medical record available, as per the trial protocol.
Demographics and disease characteristics for the total analysis set are shown in Table 1 . The median (range) observation time for the total analysis set was 3.7 (0.4-16.0) years. In the multiple sclerosis analysis set, the median (range) observation time was 1.13 years (1 day to 13.8 years) prior to subcutaneous interferon b-1a initiation and 2.03 (0-12.5) years after starting subcutaneous interferon b-1a.
Exposure to Subcutaneous Interferon b-1a
At treatment initiation, subcutaneous interferon b-1a doses were 44 mg 3 times weekly, 145 patients (47.2%) including 10 patients aged younger than 12 years (10/52; 19.5% of the children subgroup); 22 mg 3 times weekly, 117 patients (38.1%) including 32 patients aged younger than 12 years (32/52; 61.5%); other, 37 patients (12.1%) including 10 patients aged younger than 12 years (10/52, 19.2%); and unknown, 8 patients (2.6%; none aged <12 years). During the observation period, the mean (standard deviation) time on subcutaneous interferon b-1a therapy in the total analysis set was 2.12 (2.11) years; median 1.3 years (range, 1 day to 12.5 years). Overall, 82.7% (254/307) of patients were treated for at least 6 months and 59.3% (182/307) were treated for at least 12 months. A total of 99 patients permanently discontinued subcutaneous interferon b-1a therapy during the observation period. Reasons for discontinuation were clinical relapse (n ¼ 31), other medical event (n ¼ 26), patient decision (n ¼ 15), magnetic resonance imaging activity without a clinical relapse (n ¼ 9), and other reasons (n ¼ 18).
Safety and Tolerability
Overall, 61.9% (190/307) of patients had at least 1 medical event. In total, 54.7% (168/307) of patients had at least 1 prespecified medical event ( Table 2 ). The most frequently reported prespecified medical events were injection-site reactions (27.7%), influenza-like symptoms (24.4%), and hepatic disorders (14.3%). Individual prespecified medical events occurring in over 10% of patients were influenza-like illness (24.4%), injection-site erythema (15.6%), and injection-site pain (11.1%). The proportion and nature of prespecified medical events were similar in the 2 age groups, except that patients aged younger than 12 years, compared with those aged 12 to younger than 18 years, had a slightly higher incidence of injection-site erythema (19.2% vs 14.9%) and a lower incidence of injection-site pain (3.8% vs 12.5%). Nonserious medical events considered by the investigator to be related to subcutaneous interferon b-1a treatment or of unknown causality occurred in 59.9% (184/307) of patients. Excluding prespecified medical events, the most frequent nonserious medical events reported in at least 1% of patients were headache (6.2%), pyrexia (2.9%), fatigue (1.6%), depression (1.6%), nausea (1.6%), myalgia (1.3%), chills (1.3%), and upper abdominal pain (1.3%). Analysis by age group revealed slight differences in patients aged younger than 12 years compared with those aged 12 to younger than 18 years: pyrexia (5.8% vs 2.4%) and upper abdominal pain (3.8% vs 0.8%) were reported more frequently, while headache (3.8% vs 6.7%) was reported less frequently. Depression was reported only in patients aged 12 to younger than 18 years (2.0%).
There were no deaths during the study period. A total of 18 serious medical events were reported in 12 (3.9%) patients. Serious medical events occurring in patients aged 12 to younger than 18 years were injection-site injury, injection-site necrosis, and injection-site cellulitis (1 patient); convulsion, auditory hallucination, and suicidal behavior (1 patient); and, in 1 patient each, irritability, autoimmune hepatitis, cholelithiasis, idiopathic thrombocytopenic purpura, abnormal liver function test, suicidal ideation, anaphylactic reaction, and cellulitis. Only 2 patients aged younger than 12 years had serious medical events: hypersensitivity, appendectomy, and omentectomy (1 patient), and epilepsy (1 patient).
Medical events leading to dose reduction were reported in 8 (2.6%) patients; the only medical event leading to dose reduction in more than 1 patient was increased hepatic enzyme levels (2 patients). A total of 36 (11.7%) patients permanently discontinued treatment due to medical events. The most frequent events leading to treatment discontinuation were injectionsite pain (2.9%), influenza-like illness (2.0%), injection-site erythema (1.3%), and abnormal liver function test (1.3%).
The most common laboratory abnormalities were increased levels of alanine aminotransferase (74/195 patients; 37.9%) and aspartate aminotransferase (59/194; 30.4%). A similar proportion of patients aged younger than 12 years and 12 to younger than 18 years had elevated levels of alanine aminotransferase ( 
Impact of Treatment on Clinical Relapses
For the multiple sclerosis analysis set population, the annualized rate of medically confirmed clinical relapses was 1.79 in the period prior to subcutaneous interferon b-1a initiation (Figure 1) . During subcutaneous interferon b-1a treatment, the annualized relapse rate decreased to 0.47, and, in the subgroup of patients who discontinued subcutaneous interferon b-1a treatment, increased to 0.77 from the end of subcutaneous interferon b-1a treatment until the end of observation. For patients who stopped subcutaneous interferon b-1 and switched to another disease-modifying drug, the annualized relapse rate was 1.91 prior to subcutaneous interferon b-1a treatment, 0.98 during treatment, and 0.87 after stopping subcutaneous interferon b-1a. For patients who stopped all disease-modifying drug treatment, the corresponding rates were 1.85 prior to subcutaneous interferon b-1a, 0.39 during subcutaneous interferon b-1a treatment, and 0.37 after cessation of treatment. a Data are n (%). b Some patients had more than 1 event, thus the total number of events is higher than the total number of patients. c A 9-year-old patient who underwent partial resection of the greater omentum and appendectomy after 5 months on subcutaneous interferon b-1a 22 mg. Although no tumor was involved, omentectomy was classified under ''malignancy'' as it is part of the malignancy standardized Medical Dictionary for Regulatory Activities query. The treating physician considered the event as not related to subcutaneous interferon b-1a.
Similar results were observed when considering only the subgroup of patients with at least 6 months of observation before and after subcutaneous interferon b-1a initiation (Figure 1 ). The median (95% confidence interval) time to first medically confirmed clinical relapse after the first demyelinating event and prior to subcutaneous interferon b-1a initiation in the multiple sclerosis analysis set was 8.1 (6.3-9.1) months. Considering subgroups of patients by treatment status at the end of observation, the median (95% confidence interval) time to first medically confirmed clinical relapse after the first demyelinating event was 7.8 (6.3-9.7) months in patients with ongoing subcutaneous interferon b-1a treatment, 8.1 (4.2-12.3) months in patients who switched to another disease-modifying drug, and 8.4 (5.6-12.2) months in patients who stopped all disease-modifying drug treatment. After starting subcutaneous interferon b-1a therapy, the median (95% confidence interval) time to the first medicallyconfirmed clinical relapse was 19.5 (14.5-27. 2) months ( Figure  2 ). For patients receiving ongoing subcutaneous interferon b-1a therapy at the end of the study (n ¼ 203), the median (95% confidence interval) time to the first medically confirmed clinical relapse after subcutaneous interferon b-1a initiation was 26.4 (18.4-37.0) months, compared with 10.0 (7.6-14. 3) months for patients who stopped subcutaneous interferon b-1a and switched to another disease-modifying drug (n ¼ 60), and 27.2 (12.2 to not estimable) months for those who stopped subcutaneous interferon b-1a and did not switch to another disease-modifying drug (n ¼ 35).
Discussion
To date, this is the largest study assessing the safety, tolerability, and potential efficacy of subcutaneous interferon b-1a treatment in children and adolescents with multiple sclerosis. Adult doses of subcutaneous interferon b-1a (44 and 22 mg, 3 times weekly) were well tolerated in both children and adolescents with multiple sclerosis, with neither new nor unexpected adverse drug reactions. Generally, medical events were nonserious and manageable, and did not require dose reduction or treatment discontinuation. The frequency and type of medical events were consistent with those expected in adult patients with multiple sclerosis treated with subcutaneous interferon b-1a. 29, 30 Limited data are available on the use of diseasemodifying drugs to treat patients aged younger than 12 years: our study showed that there were no major differences in medical events observed in children (<12 years) compared with adolescents (12 to <18 years). A limitation of this study is that the collection of laboratory data could not be standardized due to the retrospective nature of the study design. Regularly recorded laboratory values were available for some but not all patients, making the data difficult to interpret, particularly for the group of patients aged younger than 12 years, for which data were available for fewer patients. However, from the available data, the identified laboratory abnormalities were similar across the 2 age groups. Elevations in alanine aminotransferase and aspartate aminotransferase levels, which were the most common abnormal laboratory findings in this study, are known to be associated with interferon therapy and have been reported in up to approximately 60% of adults during the first 12 months of subcutaneous interferon b-1a therapy. 31 In fact, it is recommended that, in the absence of clinical symptoms, serum alanine aminotransferase levels are monitored prior to the start of therapy; at months 1, 3, and 6 during therapy; and periodically thereafter. 31 The impact of subcutaneous interferon b-1a treatment on the frequency of clinical relapses in this study population should be interpreted with caution as there was no control group and the natural history of multiple sclerosis tends toward a reduction in the frequency of relapses over time. 8, 32 The annualized relapse rate after initiation of subcutaneous interferon b-1a treatment was lower than in the period prior to subcutaneous interferon b-1a initiation, which is in accordance with observations from smaller cohort studies of subcutaneous interferon b-1a in pediatric patients with multiple sclerosis. 23, 24 The median time to first medically confirmed clinical relapse after starting subcutaneous interferon b-1a therapy was longer than that after the first demyelinating event. Patients who were receiving ongoing subcutaneous interferon b-1a therapy at study end, or had stopped subcutaneous interferon b-1a treatment and not switched to another disease-modifying drug, had a longer median time to the first medically confirmed clinical relapse after subcutaneous interferon b-1a initiation, compared with those who had stopped subcutaneous interferon b-1a treatment and switched to another disease-modifying drug. This suggests that patients who are doing poorly on subcutaneous interferon b-1a treatment tend to switch to another diseasemodifying drug, whereas those who are doing well tend to either remain on subcutaneous interferon b-1a or cease diseasemodifying drug treatment entirely.
Given the retrospective study design, there was variability among patients with respect to concurrent medications, comorbidities, age at the time of subcutaneous interferon b-1a initiation, and dosage and duration of subcutaneous interferon b-1a treatment. Furthermore, as this was a multinational observational study, regional variation in treatment practices might have introduced bias regarding data collection, completeness of data, and patient selection. Therefore, the findings of the present study should be considered in light of the inherent limitations of retrospective analyses and require confirmation in prospective, randomized, controlled studies.
Despite the challenges inherent in a retrospective study, data from this relatively large sample of patients with pediatric-onset multiple sclerosis indicate that both children and adolescents tolerate adult doses of subcutaneous interferon b-1a without raising new safety concerns. Furthermore, treatment in this subpopulation of patients with multiple sclerosis appears to be associated with a reduction in relapse rate. informed patient consent was not obtained. Patient data were recorded anonymously.
